Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors
October 15 2020 - 3:05PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization, today
announced the appointment of Gary Sender to its Board of Directors,
effective as of October 14, 2020. Mr. Sender will replace Glenn
Chang as the Chair of iBio’s Audit Committee, who will remain a
director of the Company. Mr. Sender has also been appointed to the
Board’s Compensation Committee.
Mr. Sender is a senior executive and board
member with more than 25 years of financial leadership experience
in organizations ranging from large, multi-national pharmaceutical
firms to early-stage biotechnology companies. He is currently CFO
of Nabriva Therapeutics, a Nasdaq-listed biopharmaceutical company
engaged in the commercialization and development of novel
antibiotics to treat serious infections. Prior to joining Nabriva,
Mr. Sender was Synergy Pharmaceuticals’ Executive Vice President
and CFO. Mr. Sender previously served as Shire Plc’s Senior Vice
President of Finance & Administration, and subsequently as its
Senior Vice President of Finance.
Mr. Sender currently serves on the Board of
Directors of Schrödinger, Inc. and chairs its Audit and
Compensation Committees. He also serves on the Board of Directors
of Harmony BioSciences Inc. and chairs its Audit Committee. He
holds a bachelor’s degree in Finance and Information Systems from
Boston University and a Master of Business Administration with a
concentration in Finance from Carnegie-Mellon University.
“On behalf of everyone at the Company, I am very
pleased to welcome Mr. Sender to our team,” said Tom Isett,
Chairman & CEO of iBio. “Gary is not only an experienced
financial executive in the life science industry, but also has a
breadth of relevant public company and Board experience that should
be invaluable as iBio executes the next stages of its growth
strategy. I am confident that his expertise and guidance will be of
significant benefit to the Company and its shareholders.”
Mr. Sender commented, “I am honored to join
iBio’s Board as the Company continues to execute on its strategic
plan, building a growth-oriented biotech and pharma services
organization. iBio’s FastPharming® System and
other proprietary technologies have the potential to drive numerous
value-creating milestones over the near-, mid- and long-term.”
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming® System combines
vertical farming, automated hydroponics, and glycan engineering
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. The Company’s subsidiary,
iBio CDMO LLC, provides FastPharming Contract
Development and Manufacturing Services. iBio’s
Glycaneering Development Service™ includes an
array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing proprietary products, which include IBIO-100 for the
treatment of fibrotic diseases, and vaccines for COVID-19 disease.
For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the expected
contribution of Mr. Sender. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are subject to various risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the contribution of Mr. Sender to the Board,
the Company’s ability to obtain regulatory approvals for
commercialization of its product candidates, including its COVID-19
vaccines, or to comply with ongoing regulatory requirements,
regulatory limitations relating to its ability to promote or
commercialize its product candidates for specific indications,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, its ability
to maintain its license agreements, the continued maintenance and
growth of its patent estate, its ability to establish and maintain
collaborations, its ability to obtain or maintain the capital or
grants necessary to fund its research and development activities,
competition, its ability to retain its key employees or maintain
its NYSE American listing, and the other factors discussed in the
Company’s Annual Report on Form 10-K for the year ended June 30,
2020 and the Company’s subsequent filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. The information
in this release is provided only as of the date of this release,
and we undertake no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580 skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2024 to May 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From May 2023 to May 2024